Vimarsana
Biggest News Aggregation in the World

Page 9 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

Zanubrutinib Plus Obinutuzumab Approaches EU Approval in R/R Follicular Lymphoma - Vimarsana News

Zanubrutinib Plus Obinutuzumab Approaches EU Approval in R/R Follicular Lymphoma

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of zanubrutinib in combination with obinutuzumab for use in adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 lines of systemic treatment.

BeiGene, Ltd. (NASDAQ:BGNE) Receives $273.46 Average Target Price from Analysts - Vimarsana News

BeiGene, Ltd. (NASDAQ:BGNE) Receives $273.46 Average Target Price from Analysts

BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) has been assigned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 1-year target price among […]

BeiGene, Ltd. (NASDAQ:BGNE) Given Consensus Recommendation of "Moderate Buy" by Analysts - Vimarsana News

BeiGene, Ltd. (NASDAQ:BGNE) Given Consensus Recommendation of "Moderate Buy" by Analysts

BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the twelve analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month target price among brokerages […]

BeiGene (NASDAQ:BGNE) Lowered to "Sell" at StockNews.com - Vimarsana News

BeiGene (NASDAQ:BGNE) Lowered to "Sell" at StockNews.com

BeiGene (NASDAQ:BGNE – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Monday. BGNE has been the subject of several other reports. 22nd Century Group reaffirmed a “downgrade” rating on shares of BeiGene in a research note on Friday, […]

Citigroup Raises BeiGene (NASDAQ:BGNE) Price Target to $290.00 - Vimarsana News

Citigroup Raises BeiGene (NASDAQ:BGNE) Price Target to $290.00

BeiGene (NASDAQ:BGNE – Free Report) had its price objective hoisted by Citigroup from $285.00 to $290.00 in a research note released on Thursday morning, Marketbeat.com reports. Citigroup currently has a buy rating on the stock. A number of other analysts have also recently weighed in on BGNE. 22nd Century Group reiterated a downgrade rating on […]